Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

34.77 +0.15 (+0.43%)
Streaming Delayed Price Updated: 1:08 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Tesla, Amazon, Ambrx, BridgeBio, Azul: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition. 
Via Benzinga
These 2 Biotech Stocks Made Big Monday Moves
Find out which was the winner and which was the loser. 
Via The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P... 
Via Benzinga
Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today?
BBIO stock looks unstoppable today as BridgeBio Pharma diligently advances a treatment for a rare and unfortunate condition. 
Via InvestorPlace
Looking Into BridgeBio Pharma's Return On Capital Employed
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500... 
Via Benzinga
Why BridgeBio Pharma Stock Is Skyrocketing Today
BridgeBio's latest results could set the bar in efficacy for treating the most common cause of short stature. 
Via The Motley Fool
Stocks Rise As Bond Yields Fall; Investors Await Economic Data
Wall Street is starting the week higher, as investors look ahead to upcoming economic data and new commentary from the Federal Reserve. 
Via Talk Markets
BridgeBio's Dwarfism Candidate Shows Favorable Height Increase, Safety Profile
BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the... 
Via Benzinga
What's Going On With Kala Pharmaceuticals Shares Today
Kala Pharmaceutical (NASDAQ: KALA) shares skyrocketed more than 20% Monday morning on higher-than-average volume. On an average market day, Kala shares trade about 2.5 million times throughout the... 
Via Benzinga
Kennedy-Wilson, Radian Group, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
What's Going On With Avalon GloboCare Shares Today
The overall market ticked slightly higher in pre-market trading Monday morning, but Avalon Globocare Corp (NASDAQ: ALBT) shares really took off. Avalon GloboCare is a biotech company headquartered in... 
Via Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
Why BridgeBio Pharma Stock Is Hitting New 52-Week Highs Monday
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 study of 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in February and March Investor Events
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Why BridgeBio Pharma Stock Is Shooting Higher
BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else? 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.